Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 690% above its 5-year average of 12.65%, near the high end of its 5-year range (-3900.00%–386.75%).
400.00% above its 12-month average of 20.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
20.00%
GROSS MARGIN AVG 3Y
12.99%
GROSS MARGIN AVG 5Y
12.65%
GROSS MARGIN AVG 10Y
27.59%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+400.00%
CURRENT VS 3Y AVG
+669.86%
CURRENT VS 5Y AVG
+690.22%
CURRENT VS 10Y AVG
+262.39%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.03%
median of 851 covered companies
CURRENT VS SECTOR MEDIAN
+143.72%
vs the sector median at left
Avalo Therapeutics, Inc.
Market Cap
$702.28M
Gross Margin
100.00%
TTM Avg
20.00%
3Y Avg
12.99%
5Y Avg
12.65%
Market Cap
$698.13M
Gross Margin
-16.57%
TTM Avg
15.14%
3Y Avg
17.91%
5Y Avg
27.64%
Market Cap
$697.52M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$712.63M
Gross Margin
60.02%
TTM Avg
59.55%
3Y Avg
55.45%
5Y Avg
55.70%
Market Cap
$718.03M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$721.26M
Gross Margin
53.23%
TTM Avg
53.64%
3Y Avg
56.38%
5Y Avg
57.18%
Market Cap
$682.26M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
33.33%
Market Cap
$727.70M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $702.28M | 100.00% | 20.00% | 12.99% | 12.65% |
| Anteris Technologies Global Corp. (AVR)vs › | $698.13M | -16.57% | 15.14% | 17.91% | 27.64% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $712.63M | 60.02% | 59.55% | 55.45% | 55.70% |
| Faeth Therapeutics, Inc. (FTH)vs › | $718.03M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytek Biosciences, Inc. (CTKB)vs › | $721.26M | 53.23% | 53.64% | 56.38% | 57.18% |
| Solid Biosciences Inc. (SLDB)vs › | $682.26M | 0.00% | 0.00% | 25.00% | 33.33% |
| Verastem, Inc. (VSTM)vs › | $679.70M | 86.69% | 91.43% | 70.72% | 74.12% |
| Candel Therapeutics, Inc. (CADL)vs › | $727.70M | 0.00% | 0.00% | 25.00% | 50.00% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $728.66M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 54.69% |
| 2024-09-30 | 386.75% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 138.70% |
| 2023-09-30 | -1.69% |
| 2023-06-30 | -10.11% |
| 2023-03-31 | -949.05% |
| 2022-12-31 | 30.80% |
| 2022-09-30 | 96.47% |
| 2022-06-30 | -51.69% |
| 2022-03-31 | 38.62% |
| 2021-12-31 | -3900.00% |
| 2021-09-30 | 32.74% |
| 2021-06-30 | -196.81% |
| 2021-03-31 | 83.72% |
| 2020-12-31 | -608.82% |
| 2020-09-30 | 93.07% |
| 2020-06-30 | 94.17% |
| 2020-03-31 | 97.60% |
| 2019-12-31 | 56.35% |
| 2019-09-30 | 74.43% |
| 2019-06-30 | 27.71% |
| 2019-03-31 | 64.00% |
| 2018-12-31 | 58.26% |
| 2018-09-30 | 23.65% |
| 2018-06-30 | 70.26% |
| 2018-03-31 | 80.73% |
| 2017-12-31 | -27213.97% |
| 2017-09-30 | 97.78% |
| 2017-06-30 | -50.19% |
| 2017-03-31 | -34.30% |
| 2016-12-31 | -130.77% |
| 2016-09-30 | -1167.20% |
| 2016-06-30 | -204.69% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 50.00% |
| 2012-12-31 | 0.00% |
